100% Same
Salt CompositionEffectivenessStrength
Top Branded
Substitute
Salt Composition in bothYou Searched
Eleftha 440mg Injection
Intas Pharmaceuticals Ltd.
₹20,482
Our Recommendation
Hervycta 440mg Injection 1s
382+ trust this
WHO GMP Certified
WHO GMP
Certified
Long Expiry
(>8 Months)
WHO GMP
Certified
Long Expiry
(>8 Months)
Delivery by
Used In
Breast cancer / Stomach cancer
Customers also bought
More About Eleftha
Benefits
In Breast cancer Eleftha 440mg Injection is used to treat breast cancer when other medicines have failed to show significant improvement. It helps to stop cancer growth and further spread and relieves the symptoms of breast cancer such as breast lumps, bloody discharge from nipple or changes in the shape or texture of the breast. This medicine is given as an injection by a doctor or nurse. Follow your doctor?s instructions carefully to get the most benefit. In Stomach cancer Stomach cancer also known as gastric cancer, may occur in the inner lining (called mucosa) of the stomach or in the walls of the stomach. These are of various kinds depending on the origin, affected area and severity of the cancer. Eleftha 440mg Injection helps to kill the cancer cells and also stops their further growth and spread. Follow your doctor?s instructions carefully to get the most benefit.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How it works
Eleftha 440mg Injection is a recombinant Ig G1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the over-proliferation of cancer cells in breast cancer and stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways.
Unsafe: Avoid consuming alcohol with Eleftha 440mg Injection as it is deemed unsafe.
Seek medical advice from your doctor: Eleftha 440mg Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Doctor consultation is advised.
Seek medical advice from your doctor: Eleftha 440mg Injection is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Seek medical advice from your doctor: It is not known whether Eleftha 440mg Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Safe when prescribed by an expert: Eleftha 440mg Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Eleftha 440mg Injection may not be needed in these patients. Doctor consultation is advised.
Seek medical advice from your doctor: There is limited information available on the use of Eleftha 440mg Injection in patients with liver disease. Doctor consultation is advised.
What if I forget to take it?
If a dose of Eleftha 440mg Injection is missed, it's advisable to consult your doctor.
Manufacturer Address
Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad - 380009. Gujarat. India.
References
Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilmans: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1737
Lake DF, Briggs AD, Akporiaye ET. Immunopharmacology. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 978
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1390-91
Trastuzumab. South San Francisco, California: Genentech, Inc.; 1998 (27 Mar. 2019)
Drugs and Lactation Database (LactMed) (19 Feb. 2020)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
